Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;43(8):968-973.
doi: 10.1017/ice.2021.281. Epub 2021 Jun 24.

Clinical evaluation of Sofia Rapid Antigen Assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among emergency department to hospital admissions

Affiliations

Clinical evaluation of Sofia Rapid Antigen Assay for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among emergency department to hospital admissions

Richard D Smith et al. Infect Control Hosp Epidemiol. 2022 Aug.

Abstract

Objective: To determine the utility of the Sofia SARS rapid antigen fluorescent immunoassay (FIA) to guide hospital-bed placement of patients being admitted through the emergency department (ED).

Design: Cross-sectional analysis of a clinical quality improvement study.

Setting: This study was conducted in 2 community hospitals in Maryland from September 21, 2020, to December 3, 2020. In total, 2,887 patients simultaneously received the Sofia SARS rapid antigen FIA and SARS-CoV-2 RT-PCR assays on admission through the ED.

Methods: Rapid antigen results and symptom assessment guided initial patient placement while confirmatory RT-PCR was pending. The sensitivity, specificity, positive predictive values, and negative predictive values of the rapid antigen assay were calculated relative to RT-PCR, overall and separately for symptomatic and asymptomatic patients. Assay sensitivity was compared to RT-PCR cycle threshold (Ct) values. Assay turnaround times were compared. Clinical characteristics of RT-PCR-positive patients and potential exposures from false-negative antigen assays were evaluated.

Results: For all patients, overall agreement was 97.9%; sensitivity was 76.6% (95% confidence interval [CI], 71%-82%), and specificity was 99.7% (95% CI, 99%-100%). We detected no differences in performance between asymptomatic and symptomatic individuals. As RT-PCR Ct increased, the sensitivity of the antigen assay decreased. The mean turnaround time for the antigen assay was 1.2 hours (95% CI, 1.0-1.3) and for RT-PCR it was 20.1 hours (95% CI, 18.9-40.3) (P < .001). No transmission from antigen-negative/RT-PCR-positive patients was identified.

Conclusions: Although not a replacement for RT-PCR for detection of all SARS-CoV-2 infections, the Sofia SARS antigen FIA has clinical utility for potential initial timely patient placement.

PubMed Disclaimer

Conflict of interest statement

All authors report no conflicts of interest relevant to this article.

Figures

Fig. 1.
Fig. 1.
(A) Box plot comparing cycle thresholds of RT-PCR assays between true-positive and false-negative results for the Sofia Rapid antigen assay. True-positive antigen results had a significantly lower cycle threshold on corresponding RT-PCR assays than false-negative results. (B) Sensitivity of Sofia rapid antigen assay compared to RT-PCR assay based on cycle threshold. Sensitivity decreases as cycle threshold increases. Thus, at lower viral loads, the likelihood of false-negative antigen test results is higher.
Fig. 2.
Fig. 2.
Box plot comparing cycle thresholds of RT-PCR assays between symptomatic and asymptomatic individuals. No statistical differences were detected between the 2 groups (P = .78).

Comment in

References

    1. Machhi J, Herskovitz J, Senan AM, et al.The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol 2020;15:359–386 - PMC - PubMed
    1. Guidance document. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised). Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff. Food and Drug Administration website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.... Published May 2020. Accessed June 23, 2021.
    1. Nikolai LA, Meyer CG, Kremsner PG, Velavan TP.Asymptomatic SARS coronavirus 2 infection: invisible yet invincible. Int J Infect Dis 2020;100:112–116. - PMC - PubMed
    1. Ravi N, Cortade DL, Ng E, Wang SX.Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens Bioelectron 2020;165:112454. - PMC - PubMed
    1. Reusken C, Broberg EK, Haagmans B, et al.Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Euro Surveill 2020;25(6):2000082. - PMC - PubMed